# US 2019/0167799 A1 · Ether type glycerophospholipid-containing composition and method for producing the same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0167799 A1 - Document ID: US20190167799A1 - Status: Published application - Kind: A1 - Application number: 16/092,696 - Filed: 2016-04-27 - Published: 2019-06-06 - Earliest claimed: 2016-04-27 - Assignees: B&S Corporation:Kk - Applicants: B&S Corporation:Kk - Inventors: Yasuhiro SASUGA; Masaru FUKUI; Takehiko FUJINO; Shiro MAWATARI - Web page: https://patentgrep.com/patent/US20190167799A1 ## CPC - A61K 47/40: Cyclodextrins; Derivatives thereof - A23J 7/00: Phosphatide compositions for foodstuffs, e.g. lecithin - A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21) - A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin - A61K 35/612: Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/16: Anti-Parkinson drugs - A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia - A61P 25/24: Antidepressants - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 37/00: Drugs for immunological or allergic disorders - A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs - A61K 2236/00: Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A23J: PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION ## Abstract To provide an ether-type glycerophospholipid-containing composition that has excellent heat stability and also has oxidation stability and storage stability. An ether-type glycerophospholipid-containing composition that comprises not more than 20 mass % of an ether-type glycerophospholipid and not less than 80 mass % of a cyclodextrin. Owing to this constitution, the ether-type glycerophospholipid is clathrated in the cyclodextrin. Thus, the ether-type glycerophospholipid-containing composition has highly excellent heat stability as well as temporal stability such as oxidation stability and storage stability even in a powdery form. ## Claims ### Claim at position 1 1-10. (canceled) ### Claim 11 An ether type glycerophospholipid-containing composition comprising: 20 mass % or less of ether type glycerophospholipid; and 80 mass % or more of cyclodextrin. ### Claim 12 (depends on 11) The ether type glycerophospholipid-containing composition according to claim 11, wherein the ether type glycerophospholipid is included in the cyclodextrin. ### Claim 13 (depends on 11) The ether type glycerophospholipid-containing composition according to claim 11, being in powder form. ### Claim 14 (depends on 11) The ether type glycerophospholipid-containing composition according to claim 11, wherein the cyclodextrin is γ-cyclodextrin. ### Claim 15 (depends on 11) The ether type glycerophospholipid-containing composition according to claim 11, wherein the ether type glycerophospholipid is obtained from a biological material by extraction and purification or is obtained by chemical synthesis. ### Claim 16 (depends on 11) The ether type glycerophospholipid-containing composition according to claim 11, comprising: less than 20 mass % of ether type glycerophospholipid; and more than 80 mass % of cyclodextrin. ### Claim 17 A method for producing an ether type glycerophospholipid-containing composition comprising: mixing together 20 mass % or less of ether type glycerophospholipid and 80 mass % or more of cyclodextrin in the presence of water and/or ethanol. ### Claim 18 (depends on 17) The method for producing an ether type glycerophospholipid-containing composition according to claim 17, wherein a mixture obtained by the mixing is subjected to drying. ### Claim 19 (depends on 18) The method for producing an ether type glycerophospholipid-containing composition according to claim 18, wherein the drying is performed by freeze drying or spray drying. ### Claim 20 An ether type glycerophospholipid-stabilizing agent wherein 80 mass % or more of the cyclodextrin is incorporated into 20 mass % or less of ether type glycerophospholipid. ### Claim 21 (depends on 12) The ether type glycerophospholipid-containing composition according to claim 12, being in powder form. ### Claim 22 (depends on 12) The ether type glycerophospholipid-containing composition according to claim 12, wherein the cyclodextrin is γ-cyclodextrin. ### Claim 23 (depends on 13) The ether type glycerophospholipid-containing composition according to claim 13, wherein the cyclodextrin is γ-cyclodextrin. ### Claim 24 (depends on 12) The ether type glycerophospholipid-containing composition according to claim 12, wherein the ether type glycerophospholipid is obtained from a biological material by extraction and purification or is obtained by chemical synthesis. ### Claim 25 (depends on 13) The ether type glycerophospholipid-containing composition according to claim 13, wherein the ether type glycerophospholipid is obtained from a biological material by extraction and purification or is obtained by chemical synthesis. ### Claim 26 (depends on 14) The ether type glycerophospholipid-containing composition according to claim 14, wherein the ether type glycerophospholipid is obtained from a biological material by extraction and purification or is obtained by chemical synthesis.